Clinical Trials Search

Official Title: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy  

Study Purpose: To evaluate whether observation results in a non-inferior recurrence free survival compared to adjuvant pembrolizumab in early-stage TNBC patients who achieve a pathological complete response after neoadjuvant chemotherapy with pembrolizumab 

Status: Recruiting

Official Title: RANDOMIZED PHASE III TRIAL OF MFOLFIRINOX +/- NIVOLUMAB VS. FOLFOX +/- NIVOLUMAB FOR FIRST-LINE TREATMENT OF METASTATIC HER2-NEGATIVE GASTROESOPHAGEAL ADENOCARCINOMA

Study Purpose: To determine if overall survival (OS) is improved in patients who received mFOLFIRINOX +/- nivolumab in comparison to FOLFOX +/- nivolumab as first-line chemotherapy for metastatic gastroesophageal adenocarcinoma

Status: Recruiting

Official Title: PHASE II/III SECOND-LINE NABPLAGEM VS. NAB-PACLITAXEL/GEMCITABINE IN BRCA1/2 OR PALB2 MUTANT METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PLATINUM)

Study Purpose: To evaluate and compare overall response rate (ORR) in patients with BRCA1/2 or PALB2 mutant pancreas cancer whose disease has progressed on front-line FOLFIRINOX treated with NABPLAGEM = nab-paclitaxel, gemcitabine, and cisplatin (arm 1) versus nab-paclitaxel and gemcitabine (arm 2)

Status: Recruiting

Official Title: A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent WHO Grade 4 Glioma 

Study Purpose: To determine whether the combination of ipilimumab and nivolumab increases the tumor response rate in patients with hypermutated recurrent glioblastoma

Status: Suspended

Official Title: PHASE 2 RANDOMIZED TRIAL OF NEOADJUVANT OR PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY FOR PERITONEAL MESOTHELIOMA

Study Purpose: To determine whether frontline treatment with carboplatin, pemetrexed, bevacizumab and atezolizumab results in a superior best response rate than carboplatin, pemetrexed and bevacizumab in patients with peritoneal mesothelioma

Status: Available

Official Title: A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy

Study Purpose: To compare the progression free survival (PFS)  and the overall survival (OS)of olaparib plus temozolomide (Arm 1) as compared to investigator’s choice (trabectedin or pazopanib) (Arm 2) for the treatment of patients with advanced uterine leiomyosarcoma who have received two or more prior lines of therapy as determined by investigator (local site) assessment.

Status: Suspended

Official Title: Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Advanced Nasopharyngeal Cancer 

Study Purpose: To determine if progression-free survival is more favorable with triplet therapy combination of Cabozantinib + Nivolumab + Ipilimumab than with doublet therapy combination of Nivolumab + Ipilimumab

Status: Recruiting

Official Title: A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib Versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma 

Study Purpose: Is the combination of palbociclib plus cemiplimab better than palbociclib alone in the treatment of advanced dedifferentiated liposarcoma that cannot be removed by surgery

Status: Recruiting

Official Title: A Phase IB/II Multi-cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer

Study Purpose: To evaluate the efficacy and safety of targeted agents plus cancer immune checkpoint therapy with atezolizumab for patients with recurrent and/or persistent endometrial cancer.

Status: Recruiting

Official Title: T-DM1 and Tucatinib Compared With T-DM1 Alone In Preventing Relapses In People With High Risk Her2-Positive Breast Cancer

Study Purpose: To compare the usual treatment with T-DM1 alone to T-DM1 plus tucatinib.

Status: Recruiting